Il WHO Collaborating Center of Bolognabased in the General Directorate for Personal Care, Health and Welfare of our Region, is mentioned in an editorial in the latest issue of the magazine Lancet Neurology by title “WHO considers treatments for multiple sclerosis among essential medicines.”
Thanks to the commitment of the Center, which worked in close collaboration with MSIF, Multiple Sclerosis International Federationfrom a few months the first three drugs for the treatment of multiple sclerosis were included in the WHO list of essential medicines. This historic decision will be of great help in allowing people with multiple sclerosis access to treatment, especially in contexts where healthcare resources are limited and the costs of these therapies are prohibitive for their country’s economic possibilities.
The three drugs inserted (rituximab, glatiramer acetate and cladribine) are not the only ones effective in treating the disease, but they represent an important first step towards broader treatment opportunities thanks to the desired collaboration between governments, the private sector, non-profit organizations and patient associations towards this common goal.
The activity of the WHO Collaborating Center of Bologna